WHO 1983.

Methods	Design: phase III randomized controlled trial Location: 13 centers in Africa, Asia, Central and South America, and Europe Time frame: recruitment began 1977; final follow‐up March 1982 Sample size estimation and outcome of focus: no information
Participants	3172 women; mean age 27.4 years Inclusion criteria: non‐breastfeeding women who chose injectable contraception Exclusion criteria: contraindication for long‐acting contraceptive methods
Interventions	1) DMPA 150 mg at 90‐day intervals (N = 1587) 2) Norethisterone enanthate (NET‐EN) 200 mg at 60‐day intervals (N = 789) 3) NET‐EN 200 mg at 60‐day intervals for 6 months then 84‐day intervals (N = 796)
Outcomes	Mean weight change by contraceptive group Follow‐up: 12 and 24 months
Notes	Method for measuring weight not mentioned
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	"Randomly allocated"
Allocation concealment (selection bias)	Unclear risk	No information
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Not feasible due to differences in injection schedules for interventions
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	No information
Incomplete outcome data (attrition bias) All outcomes	High risk	Loss to follow‐up: reportedly 10.7% DMPA; 8.9% NET‐EN 60 days; 9.8% NET‐EN 84 days Life‐table rates for total discontinuation: 71% to 74%

BMI: body mass index
 DMPA: depot medroxyprogesterone acetate
 FSH: follicle stimulating hormone
 LNG‐IUC: levonorgestrel‐releasing intrauterine contraception
 MPA: medroxyprogesterone acetate
 NET‐EN: norethisterone enanthate
 NRS: non‐randomized study
 OC: oral contraceptive
 SD: standard deviation